Clinical Trial Update: Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of NK012 in combination with carboplatin in advanced solid tumors with dose expansion in metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• NK012 (NK012)

Snippet

Sponsor: Nippon Kayaku Co., Ltd. | Conditions: Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer | Phase 1 | Status: COMPLETED